The importance of early diagnosis

By using PExA's instrument, researchers are given the opportunity to study patients’ various conditions in the early stages and to produce disease-specific results, thereby shortening lead times for developing new drugs.

Professor Anna-Carin Olin explains

Through the collection of specific microscopic particles (such as liquid droplets in an aerosol) containing lipids, proteins and DNA from the small airways, potential biomarkers for various diseases can be found. Thereby, different diseases can be studied more specifically expanding opportunities to detect diseases at an early stage.

Simple to use

Until now, nearly 1700 subjects have tested the PExA method and it has proved especially easy to use, easy for the researcher and just as easy for the person being tested. Research with our method has proven that hundreds of different proteins appear in the collected samples. It is most likely that a number of biomarkers for different diseases can be identified among these proteins through further research.

The PExA method has the potential to fundamentally change the way lung diseases are diagnosed and treated today, a step which in this case brings a substantial market potential.

The search for new biomarkers

PExA's clients consist of lung research centres within the health services, in academia and in pharmaceutical companies, all of whom are currently...


Respiratory Research Needs

Getting the correct diagnosis as early as possible can be crucial to how serious the disease becomes. A relatively...


Research areas

The PExA method can be used to develop early diagnosis of various respiratory diseases such as COPD, asthma, tuberculosis...